Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 9/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | GLP1R | P43220 | 2/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 3/20 | 0.35 |
| ▸ | GCG | P01275 | 2/20 | 0.35 |
| ▸ | GIPR | P48546 | 2/20 | 0.35 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2659483 | 1.00 | GCGR (0.44) | GCGRMAPTMCL1GLP1RCHRM5 | |
| SCHEMBL2659273 | 0.92 | GCGR (0.49) | GCGRMAPTMCL1PPARASMN1; SMN2 | |
| SCHEMBL2654237 | 0.92 | GCGR (0.49) | GCGRMAPTMCL1PPARASMN1; SMN2 | |
| SCHEMBL3329163 | 0.92 | GCGR (0.53) | GCGRMCL1GLP1RCHRM5PPARA | |
| SCHEMBL3329166 | 0.92 | GCGR (0.53) | GCGRMCL1GLP1RCHRM5PPARA | |
| SCHEMBL2653667 | 0.91 | GCGR (0.45) | GCGRMAPTMCL1GLP1RCHRM5 | |
| SCHEMBL3338020 | 0.91 | GCGR (0.45) | GCGRMAPTMCL1GLP1RCHRM5 | |
| SCHEMBL2654083 | 0.90 | GCGR (0.46) | GCGRMAPTMCL1GLP1RCHRM5 | |
| SCHEMBL2655318 | 0.90 | GCGR (0.46) | GCGRMAPTMCL1GLP1RCHRM5 | |
| SCHEMBL2653930 | 0.90 | GCGR (0.47) | GCGRMAPTMCL1GLP1RCHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084489-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084489-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084489-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100137417-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2010-06-03 | — | — | US | disclosed |
| US-20100137417-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2010-06-03 | — | — | US | disclosed |
| US-20100137417-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2010-06-03 | — | — | US | disclosed |
| EP-1856090-B1 | SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2009-10-14 | — | — | EP | disclosed |
| EP-1856090-B1 | SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2009-10-14 | — | — | EP | disclosed |
| EP-1856090-A2 | SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006086488-A2 | SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137417-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | GCGR 2/4885MAPT 4790/4885MCL1 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.